US FDA clears ovarian cancer drug for hard-to-treat disease

Close-up medical syringe with needle is lying on a table (Think Stock Photo)
Close-up medical syringe with needle is lying on a table (Think Stock Photo)

WASHINGTON (AP) — U.S. health officials have approved a new option for some women battling ovarian cancer: a drug that targets a genetic mutation seen in some highly aggressive tumors.

The Food and Drug Administration cleared the drug, Rubraca, from Clovis Oncology Inc. for women in advanced stages of the disease who have already tried at least two chemotherapy drugs. The Clovis drug targets a genetic mutation found in 15 to 20 percent of ovarian cancer patients. The FDA also approved a companion test that screens for the mutation.

About 1 percent of women will be diagnosed with ovarian cancer in their lifetime, according to the National Cancer Institute. This year an estimated 14,240 women will die from the disease in the U.S.

Currently the disease is treated with surgery or chemotherapy.

Get our hottest stories
delivered to your inbox
Sign up for News Channel 8’s Noon Newsletter to get
updates on the day’s top stories

WFLA.com provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language or racial slurs, will be banned. Please be respectful of the opinions of others and keep the conversation on topic and civil. If you see an inappropriate comment, please flag it for our moderators to review.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s